This may very well be the most undervalued stock on the market right
now. The Company receives royalties on two approved products, Raptiva,
which is marketed globally for the treatment of moderate-to-severe
plaque psoriasis, and Lucentis, which is marketed globally for the
treatment of neovascular (wet) age-related macular degeneration. It
recently just recieved an analyst upgrade. It has 3 new drugs in a
late phase 3. 1 awaiting FDA approval XOMA 052 anti-interleukin-1
(IL-1) beta antibody for diabeties . Multiple drugs in early phase 2&
3. They have huge partnerships others.Therapeutic Antibodies with SPRI
is part of the Schering-Plough Corporation, a pharmaceutical company
which reported net sales of $18.5 billion in 2008. SPRI has been a
partner for therapeutic monoclonal antibody discovery and development
against multiple targets.

XOMA Q1 (Mar '09)  Revenue= 39.70 million$
XOMA Q1 (Mar '09) Gross Profit=39.70 million $
XOMA Q1 (Mar '09) Operating income =13.77 million $
XOMA Q1 (Mar '09 )Net income= 6.24 million $
XOMA Q1 (Mar '09) Net cash from investing= 15.34$ million
Net profit margin =15.71%
Operating margin =34.69%
Return on average assets= 35.72%

This is not spam. But this stock is not one you want to miss
out on!

http://www.google.com/finance?q=NASDAQ:XOMA